Tatva Chintan Pharmachem IPO lists at 95% premium
Last Updated: 29th July 2021 - 06:33 pm
Even before Tatva Chintan Pharmachem listed on the bourses, there was already a huge expectation built around the stock. Well ahead of listing, the GMP was hinting at listing premium of 90-100%. That is exactly what it turned out to be. After a phenomenal subscription of over 180 times in the IPO, the listing response was expected to be robust. Here is the Tatva Chintan Pharmachem listing story on 29 July.
Also Read - Tatva Chintan IPO Final Subscription
With the kind of response that the IPO got, the IPO price was fixed at the upper end of the band at Rs.1,083. On 29 July, the stock of Tatva Chintan Pharmachem listed on the NSE at a price of Rs.2,111.85, a premium of 95% over the issue price. On the BSE, the stock listed at a price of Rs.2,110.80, again implying a listing premium of 95%.
On the NSE, the Tatva Chintan IPO closed at Rs.2,303.30, a first day closing premium of an impressive of 126.77% over the issue price. On the BSE, the stock closed at Rs.2,310.25, a first day closing premium of 133.19% over the issue price.
On Day-1 of listing, Tatva Chintan touched a high of Rs.2,534.20 on the NSE and a low of Rs.2,111.85. On Day-1, the Tatva Chintan stock traded a total of 78.61 lakh shares on NSE amounting to value of Rs.1,812 crore. On the NSE, Tatva was ranked Number 4 by traded value on 29 July.
On the BSE, Tatva Chintan touched a high of Rs.2,486.30 and a low of Rs.2,111.80. On the BSE, the stock traded a total of 8.99 lakh shares amounting to value of Rs.207 crore. At the close of Day-1, Tatva Chintan had a market capitalization of Rs.5,121 crore with free-float market cap of just Rs.768 crore.
Trending on 5paisa
Sachin Gupta04
5paisa Research Team
Ruchit JainDiscover more of what matters to you.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.
Want to Use 5paisa
Trading App?
